Loading
NYSEHealthcareBiotechnology
Latest quote
$6.95
$0.00 · 0.00%
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Previous close
$6.95
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Day range
Current $6.95
52-week range
Current $6.95
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
49
Mixed
Risk
72
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Day range
Current $6.95
52-week range
Current $6.95
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 170.16M USD | 227.04M USD | 251.46M USD | 477.71M USD | 313.84M USD |
| Cost of goods sold | 31.52M USD | 38.55M USD | 54.01M USD | 204.22M USD | 129.69M USD |
| Gross profit | 138.63M USD | 188.49M USD | 197.45M USD | 273.49M USD | 184.15M USD |
| Research and development | 243.77M USD | 424.06M USD | 580.62M USD | 1.05B USD | 1.15B USD |
| Selling, general, and administrative | 183.29M USD | 246.16M USD | 385.03M USD | 1.43B USD | 862.95M USD |
| Operating expenses | 453.91M USD | 748.25M USD | 1.06B USD | 2.48B USD | 2.01B USD |
| Interest income | 22.62M USD | 38.61M USD | 57.22M USD | 20.26M USD | 837K USD |
| Interest expense | — | 94K USD | 93K USD | 106K USD | 2.37M USD |
| Depreciation and amortization | 58.99M USD | 63.02M USD | 71.55M USD | 61.63M USD | 29.08M USD |
| Operating income | −315.28M USD | −559.76M USD | −864.41M USD | −2.21B USD | −1.83B USD |
| Net income | −312.76M USD | −547.03M USD | −892.87M USD | −2.1B USD | −1.83B USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.84
12.81% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 20, 2024 | 1:40 | — | — |
Effective Aug 20, 2024
1:40
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI12.05M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM8.56M0.01%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF4.46M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN3.08M0.02%14.61B USD0.24%$224.62+0.40%
iShares Biotechnology ETFIBB2.62M0.02%10.73B USD0.44%$211.92-0.88%
ROBO Global Artificial Intelligence ETFTHNQ2.49M0.56%421.3M USD0.75%$90.25+0.92%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.26M0.08%2.67B USD0.20%$67.695+0.29%
Vanguard Russell 2000 ETFVTWO2.17M0.01%17.4B USD0.06%$119.62+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBROBO Global Artificial Intelligence ETFTHNQState Street SPDR S&P Kensho New Economies Composite ETFKOMPVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
